ETFs & Funds
Home›ETFs & Funds›Fund Industry›Artisan Mid Cap Fund highlights Guardant Health after…
Artisan Mid Cap Fund highlights Guardant Health after Q2 rebound
The Artisan Mid Cap Fund investor letter pointed to its addition of Guardant Health during Q2, alongside results that beat the Russell Midcap Growth Index by 3.3 percentage points.
Artisan Partners’ second-quarter 2026 investor letter for the Artisan Mid Cap Fund said global equities rebounded sharply in Q2 after March lows, supported by resilient economic data, strong corporate earnings, and continued AI investment even as inflation concerns and delayed rate cuts persisted.
The fund reported strong performance and outperformance versus the Russell Midcap Growth Index, with its Investor Class (ARTMX) returning 17.86%, Advisor Class (APDMX) returning 17.88%, and Institutional Class (APHMX) returning 17.93% compared with 14.55% for the index.
In the letter, Artisan Mid Cap Fund highlighted Guardant Health, Inc. (NASDAQ: GH), a US precision oncology company that provides blood and tissue tests and data sets. The fund said it added Guardant Health during the quarter and described the company as a leader in liquid biopsy diagnostics based on blood draws to detect and monitor cancer and support oncologists with targeted therapy selection.
As of September 4, 2026, Guardant Health closed at $161.41 per share. Over the past year, the stock gained 168.28%, the article notes, with a 52-week range of $53.40 to $176.58 and a market capitalization of $21.66 billion.
Latest closeNasdaq Comp. 26,253.34 ▼0.6%